McDonald MM, et al. - This study offers an updated information on Sost/sclerostin in cancers targeting the bone, focusing on new revelations pertaining to its potential as a therapeutic approach to treat cancer-induced bone loss, and proposes future research required to completely understand the potential of therapeutic approaches that modulate sclerostin function. As per the accumulating evidence, a dysregulated expression of sclerostin has been seen in a number of cancers that target the bone. Furthermore, novel observations indicated a robust prevention of bone loss and preservation of bone strength consequent to pharmacological inhibition of sclerostin in preclinical models of multiple myeloma, without any apparent impacts on tumor growth. Overall, sclerostin is emerging as a valuable target to prevent the bone destruction that accompanies the growth of cancer cells in the bone.